- Algernon Pharmaceuticals Inc. (AGN) receives positive feedback from the U.S. FDA for its research on Ifenprodil to treat chronic cough
- In Algernon’s pre-clinical animal cough study, Ifenprodil shows both a dramatic reduction in cough count and a delay in cough onset
- Ifenprodil shows a statistically significant delay in the onset of the first cough
- Ifenprodil has no known taste disturbance
- Algernon Pharmaceuticals Inc. (AGN) is up 4.47 per cent and is trading at $8.41 per share as of 11:08 p.m. EST
Algernon Pharmaceuticals Inc. (AGN) has received positive feedback from the U.S. FDA for its research on Ifenprodil to treat chronic cough.
Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B).
The meeting with U.S. FDA provided guidance on the Phase 2b protocol design that was submitted by Algernon.
The U.S. FDA requested standard testing must be completed prior to beginning the Phase 2b study.
Algernon estimates the testing will take approximately 90 days to complete.
In Algernon’s pre-clinical animal cough study, Ifenprodil shows both a dramatic reduction in cough count and a delay in cough onset.
Algernon also reports positive trending data from the chronic cough part of its Phase 2 idiopathic pulmonary fibrosis and chronic cough study.
The analysis examined 24-hour and waking cough counts.
Gefapixant, another trial drug for chronic cough, was also tested in the study.
Pharmidex, conducted the in-vivo cough study.
Data from this study demonstrates that at clinically relevant doses:
- Ifenprodil shows a reduction of 42 per cent in mean cough frequency vs. untreated control.
- Gefapixant shows a 20 per cent reduction in mean cough frequency vs. untreated control.
Ifenprodil shows a statistically significant delay in the onset of the first cough.
Gefapixant also shows a reduction in cough onset, but the difference was not significant.
Ifenprodil has no known taste disturbance.
Algernon Pharmaceuticals Inc. (AGN) is up 4.47 per cent and is trading at $8.41 per share as of 11:08 p.m. EST.
